3:01 PM
 | 
Apr 12, 2019
 |  BC Extra  |  Financial News

Flagship-backed Axcella seeking NASDAQ IPO

Editor's Note: This article was updated on Apr 12, 2019 at 4:18 PM PDT

With its lead program headed for its first post-IND clinical study, Axcella proposed to raise up to $86.3 million in an IPO on NASDAQ.

Axcella Health Inc. (Cambridge, Mass.) is developing a pipeline of endogenous metabolic modulators, including five oral mixtures of multiple amino acids designed to modulate liver, muscle or blood metabolism. It has begun testing the programs in non-IND, IRB-approved clinical studies.

Based on a pre-IND meeting with FDA...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >